Alto Neuroscience Earnings Call Transcripts
Fiscal Year 2026
-
ALTO-207's combination therapy for TRD enables higher, faster dosing with robust efficacy and improved tolerability, supported by strong IP and rigorous trial execution. Multiple pipeline catalysts, including ALTO-101 and ALTO-300, are expected this year, with a cash runway through 2029.
-
The presentation highlighted a precision psychiatry pipeline with late-stage programs for depression, TRD, bipolar depression, and cognition in schizophrenia. ALTO-207 and ALTO-101 are lead assets, with pivotal trials and key readouts expected through 2027. Biomarker-driven patient selection and innovative formulations aim to improve efficacy and tolerability.
Fiscal Year 2025
-
A precision medicine approach is driving multiple phase 2 programs in psychiatric disorders, with key readouts for schizophrenia, MDD, and treatment-resistant depression expected by 2026–2027. Accelerated regulatory timelines and validated biomarkers underpin the strategy.
-
Precision psychiatry programs advance with late-stage trials in depression and cognitive impairment, leveraging biomarkers and improved trial execution. Key readouts for Alto 101, 300, and 100 are expected in 2026, while Alto 207 accelerates into phase 2B and phase 3, all supported by a strong cash position.
-
The conference highlighted a precision psychiatry platform leveraging EEG and cognitive biomarkers, with a late-stage pipeline targeting cognitive impairment in schizophrenia, treatment-resistant depression, and bipolar depression. Key programs are advancing with robust trial designs, regulatory alignment, and enhanced operational rigor.
-
A precision psychiatry platform leverages biomarkers to guide CNS drug development, with late-stage trials for treatment-resistant depression, cognitive impairment in schizophrenia, and bipolar depression. Key programs use innovative biomarkers for patient selection and outcome measurement.
-
The conference showcased advances in CNS drug development, with a focus on biomarker-guided precision psychiatry. Multiple phase II programs are underway, including innovative approaches for depression, bipolar disorder, and schizophrenia, with key data readouts expected over the next two years.
-
A precision psychiatry approach is advancing with biomarker-driven drug development, highlighted by the acquisition of Alto 207 for TRD and multiple phase II trials underway. Key programs leverage EEG and cognitive biomarkers, with regulatory support and a strong cash runway into 2028.
-
A novel dopamine agonist combination (ALTO-207) was acquired to address treatment-resistant depression, enabling rapid, higher dosing with improved tolerability and robust efficacy. The asset expands a late-stage pipeline, with a pivotal trial planned and funding secured into 2028.
-
A precision psychiatry strategy using machine learning and EEG biomarkers is advancing targeted drug development for depression and schizophrenia. Key assets, including ALTO-203, ALTO-101, and ALTO-300, are progressing through clinical milestones, with improved trial design and patient selection. The field remains open for innovation amid high unmet need.
-
A precision psychiatry platform leverages biomarkers and machine learning to match drugs to responsive patient subgroups, with ongoing phase IIb trials in depression and bipolar disorder. Interim analysis for ALTO-300 led to improved site management and a mid-2026 readout. Cash runway extends into 2028.
-
Precision psychiatry pipeline advances with four Phase 2 readouts expected by 2026 and cash runway into 2028. Lead programs ALTO-100 and ALTO-300 leverage biomarker-driven patient selection, with enhanced trial controls following compliance learnings. Early-stage assets target cognitive and motivational deficits in neuropsychiatric disorders.
-
The conference highlighted a precision psychiatry pipeline using EEG biomarkers for patient selection and dosing, with four clinical programs advancing and multiple readouts expected through 2026. Enhanced trial design and compliance measures aim to improve outcomes, and the company is well-funded into 2028.
Fiscal Year 2024
-
Multiple phase 2 trials are underway, with key readouts for ALTO-300 and ALTO-203 expected in the first half of next year. Trial designs now emphasize compliance and biomarker-driven patient selection, following learnings from the ALTO-100 trial. Each asset targets distinct mechanisms and populations, with regulatory strategy aligned to FDA enrichment guidelines.
-
The conference highlighted a precision medicine approach in neuroscience, with a lead candidate targeting depression patients identified by cognitive impairment. Upcoming trial readouts and scalable digital tools support both clinical and commercial advancement.
-
Precision psychiatry efforts are advancing with ALTO-100 Phase 2b data expected soon, leveraging a scalable cognitive biomarker to target MDD patients with poor memory. Strong operational execution, FDA-aligned enrichment design, and a large commercial opportunity position the program for potential leadership in depression treatment.
-
A precision psychiatry company is advancing four clinical programs using prospectively validated brain biomarkers to target subgroups in depression and schizophrenia. The lead program, ALTO-100, expects phase IIb data in late 2024, with a robust trial design and strong safety profile.